Flumazenil in cirrhotic patients in hepatic coma: A randomized double‐blind placebo‐controlled crossover trial
Gilles Pomier‐Layrargues, J. F. Giguère, J. Lavoie, P. Perney, S. Gagnon, M. D'Amour, J. Wells, Roger F. Butterworth – 1 January 1994 – Previous reports have suggested that “endogenous” benzodiazepines could contribute to neural inhibition in hepatic encephalopathy. RO 15‐1788 (flumazenil), a specific antagonist of brain benzodiazepine receptors, could thus reverse the neurological symptoms of hepatic encephalopathy. To test this possibility, we conducted a double‐blind, placebo‐controlled crossover trial of the efficacy of flumazenil in cirrhotic patients in hepatic coma.